Sichuan Jinshi Asia Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast [Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates substantial H1 2025 performance growth, with net profit attributable to shareholders increasing by 50.04% to 85.24% and non-recurring adjusted net profit by 31.28% to 68.55% 2025 Semi-Annual Performance Forecast Key Data | Metric | Current Period (2025 H1 Est.) | Prior Period (2024 H1) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Million Yuan) | 58.82 - 72.62 | 39.20 | 50.04% - 85.24% | | Net Profit After Non-Recurring Items (Million Yuan) | 48.62 - 62.42 | 37.04 | 31.28% - 68.55% | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company explicitly states that the financial data presented in this performance forecast remains unaudited by an accounting firm - The data in this performance forecast is unaudited by an accounting firm[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Performance growth is attributed to optimized budget and cost control, successful commercialization of new materials and machinery R&D projects, and a positive impact from non-recurring gains and losses - The company achieved a reduction in period expenses through measures such as budget optimization and cost control, fostering stable business development[4](index=4&type=chunk) - The new materials and machinery business segment saw improved revenue and gross profit due to the commercialization of certain prior R&D projects[4](index=4&type=chunk) - During the reporting period, non-recurring gains and losses are estimated to have a positive impact of approximately **10.19 million yuan** on net profit[4](index=4&type=chunk) [Other Relevant Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) This performance forecast represents preliminary financial department estimates, with final accurate data to be disclosed in the 2025 semi-annual report, cautioning investors about associated risks - This performance forecast is a preliminary estimate by the company's finance department, with specific financial data subject to the 2025 semi-annual report[5](index=5&type=chunk) [Reference Documents](index=2&type=section&id=%E4%BA%94%E3%80%81%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6) The board of directors' explanation regarding the 2025 semi-annual performance forecast is designated as a reference document in the announcement - The reference document is the board of directors' explanation regarding the 2025 semi-annual performance forecast[6](index=6&type=chunk)

金石亚药（300434）公告，预计2025年上半年净利润为5881.72万元-7261.78万元，比上年同期的 3920.22万元增长50.04%-85.24%。 ...

Core Insights - Sichuan Jinshi Yao Pharmaceutical Co., Ltd. has made significant progress in its strategic layout in the dermatological drug sector by launching the first commercialized dexamethasone ointment in China under its children's drug brand "Xiaokuai Ke" in collaboration with the innovative dermatological drug brand "Shushining" [1] - The dexamethasone ointment adheres to the principle of "simplicity equals safety," containing only the active ingredient dexamethasone and the base white vaseline, eliminating potential allergens such as preservatives, emulsifiers, and fragrances, addressing the core pain points of pediatric medication safety [1] Market Opportunity - At present, atopic dermatitis (AD) has become a core challenge in health management for Chinese families, with a patient base of 70.7 million in 2022, nearly half of whom are children and adolescents [2] - The market for AD is projected to grow at a compound annual growth rate (CAGR) of 18.6%, expected to exceed 30.5 billion yuan by 2030, with the children's segment anticipated to surpass 4.5 billion yuan [3] Product Innovation - The dexamethasone ointment is the only approved formulation of its kind in China, featuring an oil-based matrix that enhances penetration and reduces stickiness compared to traditional creams and ointments, significantly improving barrier repair efficiency [5] - The product's formulation, which includes only dexamethasone and white vaseline, minimizes skin irritation and damage, aligning with the WHO's recommendations for pediatric use of topical corticosteroids [4][5] Strategic Positioning - The launch of the dexamethasone ointment represents a strategic move for Jinshi Yao, enhancing its product matrix in the children's dermatological drug market and solidifying its brand position in the pediatric pharmaceutical sector [6][8] - The company has established six core health product lines, with the dexamethasone ointment serving as the first specialized pediatric dermatological drug, contributing to a comprehensive health ecosystem that addresses various life stages and health management needs [7][8] Long-term Vision - Jinshi Yao aims to build a sustainable health ecosystem, with the launch of the dexamethasone ointment being a critical piece of its dermatological strategy, reflecting a commitment to long-term growth and investment value [6][9] - The company's mission to "provide good medicine and serve society" aligns with national health strategies, particularly in safeguarding children's health, thereby enhancing its social responsibility and market position [10][11]

Group 1 - The company approved a related party transaction involving a product promotion agreement between its wholly-owned subsidiary Zhejiang Kuaike Pharmaceutical Co., Ltd. and its associate Hangzhou Lingye Pharmaceutical Co., Ltd. The transaction amount is expected to be no more than RMB 15 million (including tax) [1][2][6] - The promotion period for the product, dexamethasone ointment, is from the effective date of the agreement until December 31, 2026 [1][4] - The company holds a 32.4304% stake in Lingye Pharmaceutical, which is considered a related party due to the involvement of the company's chairman and president in its management [2][4] Group 2 - The product involved in the agreement is dexamethasone ointment, which is a corticosteroid used for treating various skin conditions. It has been clinically validated for efficacy and safety [4][6] - The transaction pricing is based on market rates and is deemed fair and reasonable, ensuring no harm to the interests of the company's shareholders, particularly minority shareholders [5][7] - The independent directors of the company have reviewed and approved the transaction, confirming compliance with relevant laws and regulations, and asserting that it will not adversely affect the company's financial status or operational results [7]

Group 1 - The company Sichuan Jinshi Asia Pharmaceutical Co., Ltd. plans to increase the capital of its wholly-owned subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. by 200 million RMB, raising its registered capital from 150 million RMB to 350 million RMB [1] - The board of directors approved the capital increase without requiring shareholder meeting approval, as it falls within the board's authority [1] - The capital increase does not constitute a major asset restructuring as defined by relevant regulations [1] Group 2 - The financial data for Yake Pharmaceutical shows total assets of approximately 521.99 million RMB and net assets of approximately 461.59 million RMB as of December 31, 2024 [1] - The company reported a revenue of approximately 34.09 million RMB for the year 2024, with a net loss of approximately 13.69 million RMB [1] - The first quarter of 2025 shows a revenue of approximately 5.64 million RMB and a net loss of approximately 2.35 million RMB [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-026 四川金石亚洲医药股份有限公司 领业医药为公司参股公司，公司持有其32.4304%的股份。鉴于公司董事长、 总裁马益平先生现担任领业医药董事长，公司董事盛晓霞女士现担任领业医药董 事兼总经理。此外，公司第一大股东高雅萍女士直接持有领业医药28.7332%的股 份。根据《深圳证券交易所创业板股票上市规则》有关规定，领业医药为公司关 联法人。浙江快克与领业医药签订《产品推广委托协议》构成关联交易。 根据《深圳证券交易所创业板股票上市规则》和《公司章程》等有关规定， 本次关联交易在公司董事会审批权限内，无需提交公司股东大会审议。 本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产 重组，不构成重组上市，无需经过有关部门批准。 二、关联方基本情况 （一）基本情况 1 1、关联方名称：杭州领业医药科技有限公司 关于与关联方签订产品推广委托协议暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 2025年7月4日，四川金石亚洲医药股份有限公司（以下简称"公司 ...

证券代码：300434 证券简称：金石亚药 公告编号：2025-025 四川金石亚洲医药股份有限公司 关于向全资子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、本次增资事项概述 1、本次增资的基本情况 根据公司发展战略和公司全资二级子公司浙江亚克药业有限公司（以下简称 "亚克药业"）的业务发展需要，公司全资一级子公司海南亚洲制药股份有限公 司（以下简称"亚洲制药"）拟以自有资金人民币2亿元向亚克药业增资。本次 增资完成后，亚克药业的注册资本由人民币1.5亿元增加至3.5亿元。 2、履行的审议程序 2025年7月4日，四川金石亚洲医药股份有限公司（以下简称"公司"）召开 第五届董事会第九次会议审议通过了《关于向全资子公司浙江亚克药业增资的议 案》。 根据《深圳证券交易所创业板股票上市规则》和《公司章程》等有关规定， 本次交易在公司董事会审批权限内，无需提交公司股东大会审议。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组， 不构成重组上市，无需经过有关部门批准。 二、本次增资标的基本情况 1、公司名称：浙江亚克药业有限公司 ...

证券代码：300434 证券简称：金石亚药 公告编号：2025-024 四川金石亚洲医药股份有限公司 第五届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经审核，监事会认为：本次增资事项有利于公司子公司未来业务发展，不存 在损害公司及股东尤其是中小股东合法权益的情形。 具体内容详见同日在巨潮资讯网披露的《关于向全资子公司增资的公告》（公 告编号：2025-025）。 表决结果：3 票同意，0 票反对，0 票弃权。 2、审议通过了《关于与关联方签订产品推广委托协议暨关联交易的议案》 经审核，监事会认为：本次关联交易遵循市场公允定价原则，不存在损害公 司及股东尤其是中小股东合法权益的情形；本次关联交易相关决策程序合法合规， 符合《深圳证券交易所创业板股票上市规则》、《公司章程》等相关规定。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届监事会第八次 会议于 2025 年 7 月 4 日上午以通讯表决方式召开，会议通知已于 2025 年 6 月 30 日以电子邮件或网络方式发出。本次会议应出席监事 3 人， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届董事会第九次 会议于 2025 年 7 月 4 日在浙江杭州亚科中心公司会议室以现场结合通讯表决方 式召开。本次董事会会议通知已于 2025 年 6 月 30 日以电子邮件或网络方式发出。 会议应出席董事 11 名，实际出席董事 11 名；其中，董事蒯一希、郑志勇、林强 和独立董事钟鹏、贾佑龙、赵小微以通讯表决方式出席本次会议。本次会议由董 事长马益平先生主持。公司监事、高级管理人员列席了本次会议。本次会议的召 集、召开程序符合《公司法》及《公司章程》的有关规定，会议表决合法有效。 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过了《关于向全资子公司浙江亚克药业有限公司增资的议案》 证券代码：300434 证券简称：金石亚药 公告编号：2025-023 四川金石亚洲医药股份有限公司 第五届董事会第九次会议决议公告 同意以自有资金人民币 2 亿元向公司全资二级子公司浙江亚克药业有限公 司增资，本次增资完成后，浙江亚克药 ...

Core Viewpoint - The company has signed a product promotion entrustment agreement for the drug Dinoprostone Ointment with its associate company, aiming to leverage both parties' strengths in products and channels, with no adverse impact on the company's future financial status and operating results [1] Group 1 - The agreement involves a transaction amount not exceeding 15 million yuan [1] - The promotion period is from the effective date of the agreement until December 31, 2026 [1] - The company holds a 32.43% stake in the associate company, Hangzhou Lingye Pharmaceutical [1] Group 2 - Zhejiang Kuaike Pharmaceutical will be responsible for the exclusive promotion of the product in national retail channels [1] - The transaction has been approved by the company's board of directors, with related directors abstaining from voting [1] - The agreement is expected to utilize the advantages of both parties effectively [1]